Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE): Protocol for a mixed-methods research study

Yuanyuan Chen, Ziyu Tian, Shuyan Wang, Hongmei Liu, Yanfang Liu, Wei Peng, Xinxing Lai, Dahe Qi, Lingbo Kong, Ying Gao, Yuanyuan Chen, Ziyu Tian, Shuyan Wang, Hongmei Liu, Yanfang Liu, Wei Peng, Xinxing Lai, Dahe Qi, Lingbo Kong, Ying Gao

Abstract

Background: As the only traditional Chinese medicine injection approved by the China Food and Drug Administration for use as stroke first aid in ambulances, Xingnaojing Injection (XNJI) has been widely used in cases of both acute ischemic stroke (IS) and intracerebral hemorrhage (ICH). However, there is no robust clinical evidence regarding the efficacy and safety of the early use of XNJI during stroke first aid. The main purpose of this trial is to observe whether XNJI, intravenously administered within 24 h of onset in the prehospital ambulance setting, protects against early neurological deterioration (END) on the third day of onset in patients with acute stroke. Methods: The Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE) is a Mixed-Methods research (MMR) study that involves a combination of quantitative and qualitative research. The quantitative research part of this project is a prospective, multicenter, observational, clinical registry study, for which we aimed to recruit 1,000 patients with acute stroke (IS and ICH). Based on our observation of whether XNJI was intravenously administered within 24 h of onset in the prehospital ambulance setting, patients with acute stroke will be divided into two groups: the exposure group comprising patients who were intravenously administered XNJI and the nonexposure group comprising patients who were not. The primary outcome is early neurological deterioration (END) on the third day of onset defined as an increase of 2 or more points in the National Institute of Health Stroke Scale score between baseline and day 3. In addition, based on the aforementioned quantitative research, qualitative research will be conducted by interviewing emergency doctors about their knowledge and attitude regarding XNJI used for stroke first aid. Discussion: The results of the TRACE study will provide preliminary evidence for the relationship between XNJI used within 24 h of onset and the presence of END on the third day after stroke onset; it will aid in improving the current knowledge regarding the early use of XNJI for stroke first aid. Clinical Trial Registration: clinicaltrials.gov, identifier NCT04275349.

Keywords: acute stroke; mixed methods research; prehospital intervention; study protocol; traditional chinese medicine; xingnaojing injection.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Chen, Tian, Wang, Liu, Liu, Peng, Lai, Qi, Kong and Gao.

Figures

FIGURE 1
FIGURE 1
Flowchart of the TRACE study. Abbreviations: TRACE, Trial of a prehospital intervention with traditional Chinese medicine for acute stroke; BEFAST, Balance-Eyes-Face-Arms-Speech-Time; XNJI, Xingnaojing Injection; NIHSS, National Institutes of Health Stroke Scale; CT, Computed Tomography; MRI, Magnetic Resonance Imaging; ICH, intracerebral hemorrhage; BI, Barthel Index; mRS, modified Rankin Scale.

References

    1. Celik O., Cil C., Biteker F. S., Gokcek A., Dogan V. (2019). Early neurological deterioration in acute ischemic stroke. J. Chin. Med. Assoc. 82 (3), 245. 10.1097/JCMA.0000000000000022
    1. Chen H., Gong X., Xu D., Wang Z., Hu H., Wu C., et al. (2019). Advanced treatment time improves outcomes of patients with ischemic stroke undergoing reperfusion therapy. Zhejiang Univ. ( Med. Sci.) 48 (3), 247–253. 10.3785/j.issn.1008-9292.2019.06.03
    1. Deng L., Tian L., Wang H. (2010). Research progress on clinical application of angong niuhuangwan and its derivative prescription. Chin. J. Exp. Traditional Med. Formulae 16, 215–219. 10.13422/j.cnki.syfjx.2010.12.053
    1. Deng L., Wu B. (2021). Key points and interpretation of the updated guide for diagnosis and treatment of cerebral bleeding in china 2019. Cardio-Cerebrovasc. Dis. Prev. Treat. 21 (1), 13–17+34.
    1. Department of Neurology, C.S.o.T.C.a.W.M. (2018). Guidelines to combining chinese and western medicine for the treatment of cerebral infarction in china (2017). CJITWM 38 (2), 136–144. 10.3969/j.ISSN.1007-9572.2016.30.001
    1. Feng L., Kong L., Dong X., Lai X., Zhang D., Ren B., et al. (2021). China stroke registry for patients with traditional Chinese medicine (CASES-TCM): rationale and design of a prospective, multicenter, observational study. Front. Pharmacol. 12, 743883. 10.3389/fphar.2021.743883
    1. Gao L. (2016). Expert consensus on hypertensive intracerebral hemorrhage in acute stage in diagnosis and treatment combining traditional Chinese medicine and Western medicine. Chin. Gen. Pract. 19 (30), 3641–3648. 10.3969/j.ISSN.1007-9572.2016.30.001
    1. GBD 2019 Stroke Collaborators (2021). Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. Neurol. 20 (10), 795–820. 10.1016/s1474-4422(21)00252-0
    1. Geng H. H., Wang Q., Li B., Cui B. B., Jin Y. P., Fu R. L., et al. (2017). Early neurological deterioration during the acute phase as a predictor of long-term outcome after first-ever ischemic stroke. Med. Baltim. 96 (51), e9068. 10.1097/MD.0000000000009068
    1. Group, R.o.s.p.a.t.i.C.W. (2020). Brief report on stroke prevention and treatment in China, 2019. Chin. J. Cerebrovasc. Dis. 17 (5), 272–281. 10.3969/j.issn.1672-5921.2020.05.008
    1. Hurford R., Sekhar A., Hughes T. A. T., Muir K. W. (2020). Diagnosis and management of acute ischaemic stroke. Pract. Neurol. 20 (4), 304–316.
    1. Kang L., Kong L., Gao Y. (2021). TCM pathogenesis of early neurological deterioration in acute ischemic stroke based on the theory of toxin and Xuanfu. J. Beijing Univ. Trad. Chin. Med. 44, 625–630. 10.3969/j.issn.1006-2157.2021.07.007
    1. Kwan J., Hand P. (2006). Early neurological deterioration in acute stroke: clinical characteristics and impact on outcome. Qjm 99 (9), 625–633. 10.1093/qjmed/hcl082
    1. Lai X., Cao K., Kong L., Liu Q., Gao Y., investigators X. s., et al. (2017). Xingnaojing for moderate-to-severe acute ischemic stroke (XMAS): study protocol for a randomized controlled trial. Trials 18 (1), 479. 10.1186/s13063-017-2222-y
    1. Ma R., Xu H., Yang X., Wang G. (2019). Research progress in the treatment of acute stroke. Chongqing Med. 48, 1010–1013. 10.3969/j.issn.1671-8348.2019.06.029
    1. Ma L., Li D., Li K. (2013). The clinical curative effect of Xingnaojing injection for acute ischemic stroke: A systematic review. Liaoning J. Traditonal Chin. Med. 40 (4), 734–735. 10.13192/j.ljtcm.2013.04.132.malh.007
    1. Powers W. J., Rabinstein A. A., Ackerson T., Adeoye O. M., Bambakidis N. C., Becker K., et al. (2019). Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke 50 (12), e344–e418. 10.1161/STR.0000000000000211
    1. Qiu R., Zhao C., Zhong C., Hu J., Guan M., Li M., et al. (2020). Application of mixed methods research in the individualized therapeutic evaluation of clinical trials of traditional Chinese medicine. Chin. J. Evid.-Based Med. 20 (8), 973–978. 10.7507/1672-2531.201911079
    1. Saver J. L. (2006). Time is brain--quantified. Stroke 37 (1), 263–266. 10.1161/01.STR.0000196957.55928.ab
    1. Schrag M., Kirshner H. (2020). Management of intracerebral hemorrhage: JACC focus seminar. J. Am. Coll. Cardiol. 75 (15), 1819–1831. 10.1016/j.jacc.2019.10.066
    1. Shen P., Cheng S., Fu S., Ding H., Li Z. (2020). The application of Xingnaojing injection in acute cerebral infarction. J. JIANGXI UNIV. TCM 32 (6), 113–115.
    1. Thanvi B., Treadwell S., Robinson T. (2008). Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms, and management. Postgrad. Med. J. 84 (994), 412–417. 10.1136/pgmj.2007.066118
    1. Tian Z. (2021). A mixed-method study on the evidence-based evaluation of early intervention of Xingnaojing injection in acute stroke and its prognostic impact on patients. Beijing: Beijing University of Chinese Medicine Press.
    1. Tian Z., Feng L., Xie Y., Xu D., Zhang C., Kong L., et al. (2021). Chinese herbal medicine xingnaojing injection for acute ischemic stroke: an overview of systematic reviews and meta-analyses. Front. Pharmacol. 12, 659408. 10.3389/fphar.2021.659408
    1. Wang J. (2022). Clinical observation on the treatment of acute cerebral hemorrhage with Angong Niuhuang pill. CJGMCM 37 (9), 1532–1534. 10.3969/j.ISSN.1003-8914.2022.09.009
    1. Wang J., Zhou X., Wang C. (2019). Clinical effect of thrombolytic therapy with recombinant tissue plasminogen activator at different time on acute ischemic stroke. Clin. Med. 39 (11), 26–28. 10.19528/j.issn.1003-3548.2019.11.010
    1. Wang L., Fan X., Chen Y., Liang X., Shen W., Zhang Y., et al. (2022). Efficacy and safety of xingnaojing injection for emergency treatment of acute ischemic stroke: a systematic review and meta-analysis. Front. Pharmacol. 13, 839305. 10.3389/fphar.2022.839305
    1. Wang M., Jia M., Du W., Zhang X., Jiao W., Chen Q., et al. (2021). Overview of systematic reviews/Meta-analysis of Xingnaojing Injection in treatment of intracerebral hemorrhage. Chin. J. Trad. Chin. Med. 46 (18), 4633–4643. 10.19540/j.cnki.cjcmm.20210622.501
    1. Wang W., Zhang H., Wang S., Xue X., Zhao X., Xiang X., et al. (2022). Treatment of acute progressive cerebral infarction with Angong Niuhuang pill. Guide China Med. 20 (10), 22–25. 10.15912/j.cnki.gocm.2022.10.004
    1. Wu B., Liu M., Liu H., Li W., Tan S., Zhang S., et al. (2007). Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke 38 (6), 1973–1979. 10.1161/strokeaha.106.473165
    1. Wu S., Wu B., Liu M., Chen Z., Wang W., Anderson C. S., et al. (2019). Stroke in China: Advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 18 (4), 394–405. 10.1016/s1474-4422(18)30500-3
    1. Yue M., Li Q., Lu C., Jiang L. (2019). Expert consensus on the clinical application of Xingnaojing injection in the treatment of acute and critical diseases (symptom). Chin. J. Hyg. Rescue ( Electron. Ed.) 5 (02), 65–70.
    1. Zhang Y., Zhou D. (2022). The research progress of neuroinflammation after intracerebral hemorrhage. Chin. J. Crit. Care Med. Apr. 42 (4), 347–352. 10.3969/j.ISSN.1002-1949.2022.04.014

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera